{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:30:49Z","timestamp":1789698649222,"version":"4.0.1"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T00:00:00Z","timestamp":1349740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"},{"start":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T00:00:00Z","timestamp":1349740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intravenous immunoglobulin (IVIg) is a blood-derived product, used for the treatment of immunodeficiency and autoimmune diseases. Since a range of immunotherapies have recently been proposed as a therapeutic strategy for Parkinson\u2019s disease (PD), we investigated the effects of an IVIg treatment in a neurotoxin-induced animal model of PD. Mice received four injections of MPTP (15 mg\/kg) at 2-hour intervals followed by a 14-day IVIg treatment, which induced key immune-related changes such as increased regulatory T-cell population and decreased CD4<jats:sup>+<\/jats:sup>\/CD8<jats:sup>+<\/jats:sup>ratio. The MPTP treatment induced significant 80% and 84% decreases of striatal dopamine concentrations (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), as well as 33% and 40% reductions in the number of nigral dopaminergic neurons (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) in controls and IVIg-treated mice, respectively. Two-way analyses of variance further revealed lower striatal tyrosine hydroxylase protein levels, striatal homovanillic acid concentrations and nigral dopaminergic neurons (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) in IVIg-treated animals. Collectively, our results fail to support a neurorestorative effect of IVIg on the nigrostriatal system in the MPTP-treated mice and even suggest a trend toward a detrimental effect of IVIg on the dopaminergic system. These preclinical data underscore the need to proceed with caution before initiating clinical trials of IVIg in PD patients.<\/jats:p>","DOI":"10.1186\/1742-2094-9-234","type":"journal-article","created":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T12:14:03Z","timestamp":1349784843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson\u2019s disease"],"prefix":"10.1186","volume":"9","author":[{"given":"Isabelle","family":"St-Amour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Par\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Drouin-Ouellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Calon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,9]]},"reference":[{"key":"726_CR1_726","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000320027","volume":"18","author":"DD Lofrumento","year":"2011","unstructured":"Lofrumento DD, Saponaro C, Cianciulli A, De Nuccio F, Mitolo V, Nicolardi G, Panaro MA: MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation 2011, 18:79\u201388.","journal-title":"Neuroimmunomodulation"},{"key":"726_CR2_726","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.exger.2007.04.010","volume":"42","author":"A Vroon","year":"2007","unstructured":"Vroon A, Drukarch B, Bol JGJM, Cras P, Brev\u00e9 JJP, Allan SM, Relton JK, Hoogland PVJM, Van Dam AM: Neuroinflammation in Parkinson\u2019s patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Exp Gerontol 2007, 42:762\u2013771.","journal-title":"Exp Gerontol"},{"key":"726_CR3_726","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0304-3940(94)90684-X","volume":"172","author":"G Boka","year":"1994","unstructured":"Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC: Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson\u2019s disease. Neurosci Lett 1994, 172:151\u2013154.","journal-title":"Neurosci Lett"},{"key":"726_CR4_726","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0304-3940(95)11686-Q","volume":"193","author":"M Mogi","year":"1995","unstructured":"Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T: Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson\u2019s disease. Neurosci Lett 1995, 193:129\u2013132.","journal-title":"Neurosci Lett"},{"key":"726_CR5_726","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","volume":"165","author":"M Mogi","year":"1994","unstructured":"Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T: Tumor necrosis factor-alpha (TNF-\u03b1) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994, 165:208\u2013210.","journal-title":"Neurosci Lett"},{"key":"726_CR6_726","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neulet.2006.12.003","volume":"414","author":"M Mogi","year":"2007","unstructured":"Mogi M, Kondo T, Mizuno Y, Nagatsu T: p53 protein, interferon-gamma, and NF-Kb levels are elevated in the parkinsonian brain. Neurosci Lett 2007, 414:94\u201397.","journal-title":"Neurosci Lett"},{"key":"726_CR7_726","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neulet.2009.10.062","volume":"468","author":"P Scalzo","year":"2010","unstructured":"Scalzo P, Kummer A, Cardoso F, Teixeira AL: Serum levels of interleukin-6 are elevated in patients with Parkinson\u2019s disease and correlate with physical performance. Neurosci Lett 2010, 468:56\u201358.","journal-title":"Neurosci Lett"},{"key":"726_CR8_726","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jneuroim.2009.08.001","volume":"216","author":"P Scalzo","year":"2009","unstructured":"Scalzo P, Kummer A, Cardoso F, Teixeira AL: Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson\u2019s disease. J Neuroimmunol 2009, 216:122\u2013125.","journal-title":"J Neuroimmunol"},{"key":"726_CR9_726","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000097237","volume":"3","author":"G Stypula","year":"1996","unstructured":"Stypula G, Kunert-Radek J, Stepien H, Zylinska K, Pawlikowski M: Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson\u2019s disease. Neuroimmunomodulation 1996, 3:131\u2013134.","journal-title":"Neuroimmunomodulation"},{"key":"726_CR10_726","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1600-0404.1999.tb00721.x","volume":"100","author":"RJ Dobbs","year":"1999","unstructured":"Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW: Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999, 100:34\u201341.","journal-title":"Acta Neurol Scand"},{"key":"726_CR11_726","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1096\/fj.09-141044","volume":"24","author":"K Varani","year":"2010","unstructured":"Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, Granieri G, Fazio P, Leung E, MacLennan S, Granieri E, Borea PA: A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson\u2019s disease. FASEB J 2010, 24:587\u2013598.","journal-title":"FASEB J"},{"key":"726_CR12_726","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cyto.2011.03.027","volume":"55","author":"A Nicoletti","year":"2011","unstructured":"Nicoletti A, Fagone P, Donzuso G, Mangano K, Dibilio V, Caponnetto S, Bendtzen K, Zappia M, Nicoletti F: Parkinson\u2019s disease is associated with increased serum levels of macrophage migration inhibitory factor. Cytokine 2011, 55:165\u2013167.","journal-title":"Cytokine"},{"key":"726_CR13_726","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s11064-009-9921-z","volume":"34","author":"KW Hofmann","year":"2009","unstructured":"Hofmann KW, Schuh AFS, Saute J, Townsend R, Fricke D, Leke R, Souza DO, Portela LV, Chaves MLF, Rieder CRM: Interleukin-6 serum levels in patients with Parkinson\u2019s disease. Neurochem Res 2009, 34:1401\u20131404.","journal-title":"Neurochem Res"},{"key":"726_CR14_726","first-page":"182","volume":"119","author":"V Brochard","year":"2008","unstructured":"Brochard V, Combadi\u00e8re B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay J-M, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S: Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2008, 119:182\u2013192.","journal-title":"J Clin Invest"},{"key":"726_CR15_726","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2165\/11533070-000000000-00000","volume":"70","author":"R Dodel","year":"2010","unstructured":"Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, Oertel W: Intravenous immunoglobulins as a treatment for Alzheimer\u2019s disease: rationale and current evidence. Drugs 2010, 70:513\u2013528.","journal-title":"Drugs"},{"key":"726_CR16_726","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10875-008-9231-2","volume":"29","author":"MR Stein","year":"2009","unstructured":"Stein MR, Nelson RP, Church JA, Wasserman RL, Borte M, Vermylen C, Bichler J: Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol 2009, 29:137\u2013144.","journal-title":"J Clin Immunol"},{"key":"726_CR17_726","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1046\/j.1423-0410.2003.00286.x","volume":"84","author":"M Ballow","year":"2003","unstructured":"Ballow M, Berger M, Bonilla FA, Buckley RH, Cunningham-Rundles CH, Fireman P, Kaliner M, Ochs HD, Skoda-Smith S, Sweetser MT, Taki H, Lathia C: Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang 2003, 84:202\u2013210.","journal-title":"Vox Sang"},{"key":"726_CR18_726","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1567-5769(03)00134-6","volume":"3","author":"CM Roifman","year":"2003","unstructured":"Roifman CM, Schroeder H, Berger M, Sorensen R, Ballow M, Buckley RH, Gewurz A, Korenblat P, Sussman G, Lemm G: Comparison of the efficacy of IGIV-C, 10% (caprylate\/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. Int Immunopharmacol 2003, 3:1325\u20131333.","journal-title":"Int Immunopharmacol"},{"key":"726_CR19_726","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1046\/j.1423-0410.2003.00285.x","volume":"84","author":"W Lebing","year":"2003","unstructured":"Lebing W, Remington KM, Schreiner C, Paul HI: Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang 2003, 84:193\u2013201.","journal-title":"Vox Sang"},{"key":"726_CR20_726","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","volume":"26","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV: Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26:513\u2013533.","journal-title":"Annu Rev Immunol"},{"key":"726_CR21_726","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jneuroim.2010.09.015","volume":"231","author":"HC Lehmann","year":"2011","unstructured":"Lehmann HC, Hartung HP: Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol 2011, 231:61\u201369.","journal-title":"J Neuroimmunol"},{"issue":"Suppl 1","key":"726_CR22_726","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1007\/s10875-010-9398-1","volume":"30","author":"B Tackenberg","year":"2010","unstructured":"Tackenberg B, Nimmerjahn F, Lunemann JD: Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. J Clin Immunol 2010,30(Suppl 1):S65-S69.","journal-title":"J Clin Immunol"},{"key":"726_CR23_726","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jneuroim.2009.01.014","volume":"209","author":"N Pigard","year":"2009","unstructured":"Pigard N, Elovaara I, Kuusisto H, Paalavuo R, Dastidar P, Zimmermann K, Schwarz HP, Reipert B: Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression. J Neuroimmunol 2009, 209:114\u2013120.","journal-title":"J Neuroimmunol"},{"key":"726_CR24_726","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2249.2011.04387.x","volume":"164","author":"SV Kaveri","year":"2011","unstructured":"Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J: Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 2011, 164:2\u20135.","journal-title":"Clin Exp Immunol"},{"key":"726_CR25_726","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10875-007-9088-9","volume":"27","author":"VS Negi","year":"2007","unstructured":"Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007, 27:233\u2013245.","journal-title":"J Clin Immunol"},{"key":"726_CR26_726","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1196\/annals.1423.052","volume":"1110","author":"S Siberil","year":"2007","unstructured":"Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci 2007, 1110:497\u2013506.","journal-title":"Ann N Y Acad Sci"},{"key":"726_CR27_726","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.intimp.2005.11.013","volume":"6","author":"J Bayary","year":"2006","unstructured":"Bayary J, Dasgupta S, Misra N, Ephrem A, Van H, Jean-Paul D, Delignat S, Hassan G, Caligiuri G, Nicoletti A, Lacroix-Desmazes S, Kazatchkine MD, Kaveri S: Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol 2006, 6:528\u2013534.","journal-title":"Int Immunopharmacol"},{"key":"726_CR28_726","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.autrev.2008.04.011","volume":"7","author":"J Vani","year":"2008","unstructured":"Vani J, Elluru S, Negi V-S, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 2008, 7:440\u2013444.","journal-title":"Autoimmun Rev"},{"key":"726_CR29_726","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/jnnp.64.2.162","volume":"64","author":"A Creange","year":"1998","unstructured":"Creange A, Belec L, Clair B, Degos JD, Raphael JC, Gherardi RK: Circulating transforming growth factor beta 1 (TGF-\u03b21) in Guillain\u2013Barre syndrome: decreased concentrations in the early course and increase with motor function. J Neurol Neurosurg Psychiatry 1998, 64:162\u2013165.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"726_CR30_726","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cyto.2007.12.007","volume":"41","author":"DB Keskin","year":"2008","unstructured":"Keskin DB, Stern JNH, Fridkis-Hareli M, Razzaque A: Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy. Cytokine 2008, 41:315\u2013321.","journal-title":"Cytokine"},{"key":"726_CR31_726","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0165-5728(00)00412-4","volume":"112","author":"M Stangel","year":"2001","unstructured":"Stangel M, Compston A: Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. J Neuroimmunol 2001, 112:63\u201371.","journal-title":"J Neuroimmunol"},{"key":"726_CR32_726","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.clim.2011.08.003","volume":"141","author":"AC Issekutz","year":"2011","unstructured":"Issekutz AC, Rowter D, MacMillan HF: Intravenous immunoglobulin G (IVIG) inhibits IL-1- and TNF-alpha-dependent, but not chemotactic-factor-stimulated, neutrophil transendothelial migration. Clin Immunol 2011, 141:187\u2013196.","journal-title":"Clin Immunol"},{"key":"726_CR33_726","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1093\/brain\/awh297","volume":"127","author":"BM Lapointe","year":"2004","unstructured":"Lapointe BM: IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 2004, 127:2649\u20132656.","journal-title":"Brain"},{"key":"726_CR34_726","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1423-0410.2008.001036.x","volume":"94","author":"BM Reipert","year":"2008","unstructured":"Reipert BM, Stellamor MT, Poell M, Ilas J, Sasgary M, Reipert S, Zimmermann K, Ehrlich H, Schwarz HP: Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox Sang 2008, 94:334\u2013341.","journal-title":"Vox Sang"},{"key":"726_CR35_726","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1742-2094-9-105","volume":"9","author":"L Puli","year":"2012","unstructured":"Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, Tanila H: Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer\u2019s disease. J Neuroinflammation 2012, 9:105.","journal-title":"J Neuroinflammation"},{"key":"726_CR36_726","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(11)70213-7","volume":"10","author":"K Vekrellis","year":"2011","unstructured":"Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L: Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 2011, 10:1015\u20131025.","journal-title":"Lancet Neurol"},{"key":"726_CR37_726","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s10495-010-0486-8","volume":"15","author":"T Yasuda","year":"2010","unstructured":"Yasuda T, Mochizuki H: The regulatory role of alpha-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson\u2019s disease. Apoptosis 2010, 15:1312\u20131321.","journal-title":"Apoptosis"},{"key":"726_CR38_726","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","volume":"6","author":"E Masliah","year":"2011","unstructured":"Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D: Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of lewy body disease. PLoS One 2011, 6:e19338.","journal-title":"PLoS One"},{"key":"726_CR39_726","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","volume":"46","author":"E Masliah","year":"2005","unstructured":"Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D: Effects of alpha-synuclein immunization in a mouse model of Parkinson\u2019s disease. Neuron 2005, 46:857\u2013868.","journal-title":"Neuron"},{"key":"726_CR40_726","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1365-2249.2010.04214.x","volume":"161","author":"LM Patrias","year":"2010","unstructured":"Patrias LM, Klaver AC, Coffey MP, Loeffler DA: Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations. Clin Exp Immunol 2010, 161:527\u2013535.","journal-title":"Clin Exp Immunol"},{"key":"726_CR41_726","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nm.2165","volume":"16","author":"JA Obeso","year":"2010","unstructured":"Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AHV, Halliday G: Missing pieces in the Parkinson\u2019s disease puzzle. Nat Med 2010, 16:653\u2013661.","journal-title":"Nat Med"},{"key":"726_CR42_726","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1353-8020(03)00044-0","volume":"9","author":"M Nomoto","year":"2003","unstructured":"Nomoto M: Clinical pharmacology and neuroprotection in Parkinson\u2019s disease. Parkinsonism Relat Disord 2003, 9:55\u201358.","journal-title":"Parkinsonism Relat Disord"},{"key":"726_CR43_726","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nprot.2006.342","volume":"2","author":"V Jackson-Lewis","year":"2007","unstructured":"Jackson-Lewis V, Przedborski S: Protocol for the MPTP mouse model of Parkinson\u2019s disease. Nat Protoc 2007, 2:141\u2013151.","journal-title":"Nat Protoc"},{"key":"726_CR44_726","doi-asserted-by":"crossref","first-page":"269","DOI":"10.55782\/ane-2011-1847","volume":"71","author":"H Yokoyama","year":"2011","unstructured":"Yokoyama H, Kuroiwa H, Kasahara J, Araki T: Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced mouse model of Parkinson\u2019s disease. Acta Neurobiol Exp 2011, 71:269\u2013280.","journal-title":"Acta Neurobiol Exp"},{"key":"726_CR45_726","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/syn.1045","volume":"40","author":"F Calon","year":"2001","unstructured":"Calon F, Lavertu N, Lemieux AM, Morissette M, Goulet M, Grondin R, Blanchet PJ, B\u00e9dard PJ, Di Paolo T: Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter. Synapse 2001, 40:225\u2013234.","journal-title":"Synapse"},{"key":"726_CR46_726","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","volume":"30","author":"NR Relkin","year":"2008","unstructured":"Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME: 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2008, 30:1728\u20131736.","journal-title":"Neurobiol Aging"},{"key":"726_CR47_726","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3233\/JAD-2007-12411","volume":"12","author":"C Tremblay","year":"2007","unstructured":"Tremblay C, Pilote M, Phivilay A, Emond V, Bennett DA, Calon F: Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimers Dis 2007, 12:377\u2013390.","journal-title":"J Alzheimers Dis"},{"key":"726_CR48_726","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.nbd.2011.09.009","volume":"45","author":"M Bousquet","year":"2012","unstructured":"Bousquet M, St-Amour I, Vandal M, Julien P, Cicchetti F, Calon F: High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice. Neurobiol Dis 2012, 45:529\u2013538.","journal-title":"Neurobiol Dis"},{"key":"726_CR49_726","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1096\/fj.07-9677com","volume":"22","author":"M Bousquet","year":"2008","unstructured":"Bousquet M, Saint-Pierre M, Julien C, Salem N, Cicchetti F, Calon F: Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson\u2019s disease. FASEB J 2008, 22:1213\u20131225.","journal-title":"FASEB J"},{"key":"726_CR50_726","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1742-2094-8-137","volume":"8","author":"J Drouin-Ouellet","year":"2011","unstructured":"Drouin-Ouellet J, Gibrat C, Bousquet M, Calon F, Kriz J, Cicchetti F: The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. J Neuroinflammation 2011, 8:137.","journal-title":"J Neuroinflammation"},{"key":"726_CR51_726","first-page":"93","volume":"28","author":"B Olivito","year":"2010","unstructured":"Olivito B, Taddio A, Simonini G, Massai C, Ciullini S, Gambineri E, de Martino M, Azzari C, Cimaz R: Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol 2010, 28:93\u201397.","journal-title":"Clin Exp Rheumatol"},{"key":"726_CR52_726","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3899\/jrheum.110981","volume":"39","author":"N Tsurikisawa","year":"2012","unstructured":"Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K: High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J Rheumatol 2012, 39:1019\u20131025.","journal-title":"J Rheumatol"},{"key":"726_CR53_726","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","volume":"111","author":"A Ephrem","year":"2008","unstructured":"Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N: Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008, 111:715\u2013722.","journal-title":"Blood"},{"key":"726_CR54_726","doi-asserted-by":"publisher","first-page":"e1002071","DOI":"10.1371\/journal.ppat.1002071","volume":"7","author":"C Ramakrishna","year":"2011","unstructured":"Ramakrishna C, Newo ANS, Shen Y-W, Cantin E: Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog 2011, 7:e1002071.","journal-title":"PLoS Pathog"},{"key":"726_CR55_726","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nri2785","volume":"10","author":"S Sakaguchi","year":"2010","unstructured":"Sakaguchi S, Miyara M, Costantino CM, Hafler DA: FoxP3(+) regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490\u2013500.","journal-title":"Nat Rev Immunol"},{"key":"726_CR56_726","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2353\/ajpath.2010.090936","volume":"177","author":"KV Poojary","year":"2010","unstructured":"Poojary KV, Kong Y-M, Farrar MA: Control of Th2-mediated inflammation by regulatory T cells. Am J Pathol 2010, 177:525\u2013531.","journal-title":"Am J Pathol"},{"key":"726_CR57_726","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.4049\/jimmunol.0901852","volume":"184","author":"AD Reynolds","year":"2010","unstructured":"Reynolds AD, Stone DK, Hutter JAL, Benner EJ, Mosley RL, Gendelman HE: Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson\u2019s disease. J Immunol 2010, 184:2261\u20132271.","journal-title":"J Immunol"},{"key":"726_CR58_726","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1189\/jlb.0507296","volume":"82","author":"AD Reynolds","year":"2007","unstructured":"Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL: Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson\u2019s disease. J Leukoc Biol 2007, 82:1083\u20131094.","journal-title":"J Leukoc Biol"},{"key":"726_CR59_726","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1474-9726.2011.00677.x","volume":"10","author":"Y Chi","year":"2011","unstructured":"Chi Y, Fan Y, He L, Liu W, Wen X, Zhou S, Wang X, Zhang C, Kong H, Sonoda L, Tripathi P, Li CJ, Yu MS, Su C, Hu G: Novel role of aquaporin-4 in CD4+\u201a CD25+ T regulatory cell development and severity of Parkinson\u2019s disease. Aging Cell 2011, 10:368\u2013382.","journal-title":"Aging Cell"},{"key":"726_CR60_726","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/eji.201041315","volume":"41","author":"C Starke","year":"2011","unstructured":"Starke C, Frey S, Wellmann U, Urbonaviciute V, Herrmann M, Amann K, Schett G, Winkler T, Voll RE: High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB\/W F1 lupus mice. Eur J Immunol 2011, 41:2107\u20132112.","journal-title":"Eur J Immunol"},{"key":"726_CR61_726","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1681\/ASN.2010010034","volume":"22","author":"J Bontscho","year":"2011","unstructured":"Bontscho J, Schreiber A, Manz RA, Schneider W, Luft FC, Kettritz R: Myeloperoxidase-specific plasma cell depletion by Bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 2011, 22:336\u2013348.","journal-title":"J Am Soc Nephrol"},{"key":"726_CR62_726","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abb.2010.12.017","volume":"508","author":"SC Daubner","year":"2011","unstructured":"Daubner SC, Le T, Wang S: Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 2011, 508:1\u201312.","journal-title":"Arch Biochem Biophys"},{"key":"726_CR63_726","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/jnr.20114","volume":"76","author":"MW Jakowec","year":"2004","unstructured":"Jakowec MW, Nixon K, Hogg E, McNeill T, Petzinger GM: Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. J Neurosci Res 2004, 76:539\u2013550.","journal-title":"J Neurosci Res"},{"key":"726_CR64_726","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/1055-8330(95)90015-2","volume":"4","author":"V Jackson-Lewis","year":"1995","unstructured":"Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S: Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257\u2013269.","journal-title":"Neurodegeneration"},{"key":"726_CR65_726","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1006\/exnr.1997.6648","volume":"148","author":"E Bezard","year":"1997","unstructured":"Bezard E, Dovero S, Bioulac B, Gross C: Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp Neurol 1997, 148:288\u2013292.","journal-title":"Exp Neurol"},{"key":"726_CR66_726","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/00008877-200609000-00003","volume":"17","author":"E Bezard","year":"2006","unstructured":"Bezard E: A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism. Behav Pharmacol 2006, 17:379\u2013382.","journal-title":"Behav Pharmacol"},{"key":"726_CR67_726","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jneuroim.2007.05.011","volume":"188","author":"D Rosenkranz","year":"2007","unstructured":"Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, Gasser T, Stoltze L: Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 2007, 188:117\u2013127.","journal-title":"J Neuroimmunol"},{"key":"726_CR68_726","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1046\/j.1365-2249.1997.d01-904.x","volume":"107","author":"P Aukrust","year":"1997","unstructured":"Aukrust P, Muller F, Nordoy I, Haug CJ, Froland SS: Modulation of lymphocyte and monocyte activity after intravenous immunoglobulin administration in vivo. Clin Exp Immunol 1997, 107:50\u201356.","journal-title":"Clin Exp Immunol"},{"key":"726_CR69_726","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1182\/blood-2005-06-2345","volume":"107","author":"T Baba","year":"2006","unstructured":"Baba T, Ishizu A, Iwasaki S, Suzuki A, Tomaru U, Ikeda H, Yoshiki T, Kasahara M: CD4+\/CD8+ macrophages infiltrating at inflammatory sites: a population of monocytes\/macrophages with a cytotoxic phenotype. Blood 2006, 107:2004\u20132012.","journal-title":"Blood"},{"key":"726_CR70_726","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0165-5728(00)00422-7","volume":"113","author":"J Bas","year":"2001","unstructured":"Bas J, Calopa M, Mestre M, MD G, Cutillas B, Ambrosio S, Buendia E: Lymphocyte populations in Parkinson\u2019s disease and in rat models of parkinsonism. J Neuroimmunol 2001, 113:146\u2013152.","journal-title":"J Neuroimmunol"},{"key":"726_CR71_726","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/archneur.58.10.1580","volume":"58","author":"K Hisanaga","year":"2001","unstructured":"Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y: Increase in peripheral CD4 bright + CD8 dull + T cells in Parkinson disease. Arch Neurol 2001, 58:1580\u20131583.","journal-title":"Arch Neurol"},{"key":"726_CR72_726","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2009.12.017","volume":"38","author":"M Calopa","year":"2010","unstructured":"Calopa M, Bas J, Callen A, Mestre M: Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol Dis 2010, 38:1\u20137.","journal-title":"Neurobiol Dis"},{"key":"726_CR73_726","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jneuroim.2006.04.023","volume":"177","author":"AD Janke","year":"2006","unstructured":"Janke AD, Giuliani F, Yong VW: IVIg attenuates T cell-mediated killing of human neurons. J Neuroimmunol 2006, 177:181\u2013188.","journal-title":"J Neuroimmunol"},{"key":"726_CR74_726","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/j.1365-2230.2004.01635.x","volume":"29","author":"K Ito","year":"2004","unstructured":"Ito K, Hara H, Okada T, Shimojima H, Suzuki H: Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-ligand expression. Clin Exp Dermatol 2004, 29:679\u2013680.","journal-title":"Clin Exp Dermatol"},{"key":"726_CR75_726","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10238-009-0061-1","volume":"10","author":"H Artac","year":"2009","unstructured":"Artac H, Kara R, Reisli I: In vivo modulation of the expressions of Fas and CD25 by intravenous immunoglobulin in common variable immunodeficiency. Clin Exp Med 2009, 10:27\u201331.","journal-title":"Clin Exp Med"},{"key":"726_CR76_726","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1742-2094-7-90","volume":"7","author":"J Magga","year":"2010","unstructured":"Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, Hartig W, Grosche J, Goldsteins G, Tanila H, Koistinaho J, Koistinaho M: Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer\u2019s disease. J Neuroinflammation 2010, 7:90.","journal-title":"J Neuroinflammation"},{"key":"726_CR77_726","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.4049\/jimmunol.1100620","volume":"187","author":"M Kitazawa","year":"2011","unstructured":"Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM: Blocking IL-1 signaling rescues cognition, attenuates Tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer\u2019s disease model. J Immunol 2011, 187:6549.","journal-title":"J Immunol"},{"key":"726_CR78_726","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/nn968","volume":"5","author":"J Tan","year":"2002","unstructured":"Tan J, Town T, Crawford F, Mori T, Delledonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ: Role of CD40 ligand in amyloidosis in transgenic Alzheimer\u2019s mice. Nat Neurosci 2002, 5:1288\u20131293.","journal-title":"Nat Neurosci"},{"key":"726_CR79_726","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12017-009-8099-5","volume":"12","author":"E Okun","year":"2010","unstructured":"Okun E, Mattson M, Arumugam T: Involvement of Fc receptors in disorders of the central nervous system. Neuromol Med 2010, 12:164\u2013178.","journal-title":"Neuromol Med"},{"key":"726_CR80_726","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1093\/brain\/awh625","volume":"128","author":"CF Orr","year":"2005","unstructured":"Orr CF: A possible role for humoral immunity in the pathogenesis of Parkinson\u2019s disease. Brain 2005, 128:2665\u20132674.","journal-title":"Brain"},{"key":"726_CR81_726","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/mds.23696","volume":"26","author":"E Bezard","year":"2011","unstructured":"Bezard E, Przedborski S: A tale on animal models of Parkinson\u2019s disease. Mov Disord 2011, 26:993\u20131002.","journal-title":"Mov Disord"},{"key":"726_CR82_726","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty S, Jenner P: Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 2011, 164:1357\u20131391.","journal-title":"Br J Pharmacol"},{"key":"726_CR83_726","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.tips.2004.03.003","volume":"25","author":"W Meissner","year":"2004","unstructured":"Meissner W, Hill MP, Tison F, Gross CE, Bezard E: Neuroprotective strategies for Parkinson\u2019s disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 2004, 25:249\u2013253.","journal-title":"Trends Pharmacol Sci"},{"key":"726_CR84_726","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF01249445","volume":"38","author":"P Riederer","year":"1976","unstructured":"Riederer P, Wuketich S: Time course of nigrostriatal degeneration in parkinson\u2019s disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976, 38:277\u2013301.","journal-title":"J Neural Transm"},{"key":"726_CR85_726","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","volume":"20","author":"H Bernheimer","year":"1973","unstructured":"Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20:415\u2013455.","journal-title":"J Neurol Sci"},{"key":"726_CR86_726","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/mds.21010","volume":"21","author":"GE Meredith","year":"2006","unstructured":"Meredith GE, Kang UJ: Behavioral models of Parkinson\u2019s disease in rodents: a new look at an old problem. Mov Disord 2006, 21:1595\u20131606.","journal-title":"Mov Disord"},{"key":"726_CR87_726","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bbr.2011.11.019","volume":"228","author":"L Chagniel","year":"2012","unstructured":"Chagniel L, Robitaille C, Lacharit\u00e9-Mueller C, Bureau G, Cyr M: Partial dopamine depletion in MPTP-treated mice differentially altered motor skill learning and action control. Behav Brain Res 2012, 228:9\u201315.","journal-title":"Behav Brain Res"},{"key":"726_CR88_726","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11481-011-9269-4","volume":"7","author":"JAL Hutter-Saunders","year":"2011","unstructured":"Hutter-Saunders JAL, Gendelman HE, Mosley RL: Murine motor and behavior functional evaluations for acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication. J Neuroimmune Pharmacol 2011, 7:279\u2013288.","journal-title":"J Neuroimmune Pharmacol"},{"key":"726_CR89_726","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0969-9961(03)00108-6","volume":"14","author":"E Rousselet","year":"2003","unstructured":"Rousselet E, Joubert C, Callebert J, Parain K, Tremblay L, Orieux G, Launay J-M, Cohen-Salmon C, Hirsch EC: Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol Dis 2003, 14:218\u2013228.","journal-title":"Neurobiol Dis"},{"key":"726_CR90_726","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S1353-8020(02)00115-3","volume":"9","author":"P Jenner","year":"2003","unstructured":"Jenner P: The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson\u2019s disease. Parkinsonism Relat Disord 2003, 9:131\u2013137.","journal-title":"Parkinsonism Relat Disord"},{"key":"726_CR91_726","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.molbrainres.2005.01.012","volume":"134","author":"M Shimoji","year":"2005","unstructured":"Shimoji M, Zhang L, Mandir A, Dawson V, Dawson T: Absence of inclusion body formation in the MPTP mouse model of Parkinson\u2019s disease. Mol Brain Res 2005, 134:103\u2013108.","journal-title":"Mol Brain Res"},{"key":"726_CR92_726","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1046\/j.1471-4159.2000.740721.x","volume":"74","author":"M Vila","year":"2000","unstructured":"Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S: Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 2000, 74:721\u2013729.","journal-title":"J Neurochem"},{"key":"726_CR93_726","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1111\/j.1471-4159.2009.06072.x","volume":"109","author":"C Gibrat","year":"2009","unstructured":"Gibrat C, Saint-Pierre M, Bousquet M, L\u00e9vesque D, Rouillard C, Cicchetti F: Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J Neurochem 2009, 109:1469\u20131482.","journal-title":"J Neurochem"},{"key":"726_CR94_726","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1073\/pnas.0409713102","volume":"102","author":"F Fornai","year":"2005","unstructured":"Fornai F, Schl\u00fcer OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, S\u00fcdhof TC: Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 2005, 102:3413\u20133418.","journal-title":"Proc Natl Acad Sci USA"},{"key":"726_CR95_726","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1155\/2012\/845618","volume":"2012","author":"J Blesa","year":"2012","unstructured":"Blesa J, Phani S, Jackson-Lewis V, Przedborski S: Classic and new animal models of Parkinson\u2019s disease. J Biomed Biotechnol 2012, 2012:10. Article ID 845618, doi:10.1155\/2012\/845618","journal-title":"J Biomed Biotechnol"},{"key":"726_CR96_726","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1537-2995.2009.02558.x","volume":"50","author":"Y Katsman","year":"2010","unstructured":"Katsman Y, Foo AH, Leontyev D, Branch DR: Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction. Transfusion 2010, 50:1285\u20131294.","journal-title":"Transfusion"},{"key":"726_CR97_726","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1182\/blood-2009-06-225417","volume":"115","author":"E Aubin","year":"2010","unstructured":"Aubin E, Lemieux R, Bazin R: Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 2010, 115:1727\u20131734.","journal-title":"Blood"},{"key":"726_CR98_726","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/0961203309355299","volume":"19","author":"Z Racz","year":"2010","unstructured":"Racz Z, Nagy E, Rosivall L, Szebeni J, Hamar P: Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not renal disease in the MRL\/lpr mouse model of systemic lupus. Lupus 2010, 19:599\u2013612.","journal-title":"Lupus"},{"key":"726_CR99_726","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.neuint.2011.06.013","volume":"59","author":"O Gonzalez-Flores","year":"2011","unstructured":"Gonzalez-Flores O, Gomora-Arrati P, Garcia-Juarez M, Miranda-Martinez A, Armengual-Villegas A, Camacho-Arroyo I, Guerra-Araiza C: Progesterone receptor isoforms differentially regulate the expression of tryptophan and tyrosine hydroxylase and glutamic acid decarboxylase in the rat hypothalamus. Neurochem Int 2011, 59:671\u2013676.","journal-title":"Neurochem Int"},{"key":"726_CR100_726","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/j.neuropharm.2012.02.003","volume":"62","author":"B Bosier","year":"2012","unstructured":"Bosier B, Muccioli GG, Mertens B, Sarre S, Michotte Y, Lambert DM, Hermans E: Differential modulations of striatal tyrosine hydroxylase and dopamine metabolism by cannabinoid agonists as evidence for functional selectivity in vivo. Neuropharmacology 2012, 62:2327\u20132335.","journal-title":"Neuropharmacology"},{"key":"726_CR101_726","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/216464","volume":"2011","author":"MFR Ferrari","year":"2011","unstructured":"Ferrari MFR, Coelho EF, Farizatto KLG, Chadi G, Fior-Chadi DR: Modulation of tyrosine hydroxylase, neuropeptide Y, glutamate, and substance P in ganglia and brain areas involved in cardiovascular control after chronic exposure to nicotine. Int J Hypertens 2011, 2011:1\u20139.","journal-title":"Int J Hypertens"},{"key":"726_CR102_726","doi-asserted-by":"publisher","first-page":"14524","DOI":"10.1073\/pnas.172514599","volume":"99","author":"W Dauer","year":"2002","unstructured":"Dauer W, Kholodilov N, Vila M, Trillat A-C, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke R, Hen R: Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 2002, 99:14524\u201314529.","journal-title":"Proc Natl Acad Sci USA"},{"key":"726_CR103_726","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0306-4522(03)00036-8","volume":"118","author":"OM Schluter","year":"2003","unstructured":"Schluter OM, Fornai F, Alessandri MG, Takamori S, Geppert M, Jahn R, Sudhof TC: Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 2003, 118:985\u20131002.","journal-title":"Neuroscience"},{"key":"726_CR104_726","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.neuro.2004.05.002","volume":"25","author":"RE Drolet","year":"2004","unstructured":"Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL: Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 2004, 25:761\u2013769.","journal-title":"Neurotoxicology"},{"key":"726_CR105_726","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.1471-4159.2004.02378.x","volume":"89","author":"DC Robertson","year":"2004","unstructured":"Robertson DC, Schmidt O, Ninkina N, Jones PA, Sharkey J, Buchman VL: Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha\/gamma-synuclein null mutant mice. Neurochem 2004, 89:1126\u20131136.","journal-title":"Neurochem"},{"key":"726_CR106_726","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.nbd.2005.08.018","volume":"21","author":"P Klivenyi","year":"2006","unstructured":"Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, Ferrante RJ, Kowall NW, Abeliovich A, Beal MF: Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 2006, 21:541\u2013548.","journal-title":"Neurobiol Dis"},{"key":"726_CR107_726","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1471-4159.2006.04365.x","volume":"101","author":"KK Papachroni","year":"2006","unstructured":"Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, Papadimitriou A, Kalofoutis A, Buchman VL: Autoantibodies to alpha-synuclein in inherited Parkinson\u2019s disease. J Neurochem 2006, 101:749\u2013756.","journal-title":"J Neurochem"},{"key":"726_CR108_726","doi-asserted-by":"publisher","first-page":"e18513","DOI":"10.1371\/journal.pone.0018513","volume":"6","author":"K Yanamandra","year":"2011","unstructured":"Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA: Alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson\u2019s disease patients. PLoS One 2011, 6:e18513.","journal-title":"PLoS One"},{"key":"726_CR109_726","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1006\/exnr.2002.7946","volume":"176","author":"Y He","year":"2002","unstructured":"He Y, Le W-D, Appel SH: Role of Fc\u03b3 receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 2002, 176:322\u2013327.","journal-title":"Exp Neurol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-2094-9-234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/1742-2094-9-234\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-2094-9-234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-2094-9-234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T04:34:24Z","timestamp":1714451664000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/1742-2094-9-234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,9]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1186\/1742-2094-9-234","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,9]]},"assertion":[{"value":"25 May 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"234"}}